Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin vs Placebo in Advanced Colorectal Carcinoma (CO.23)
NCT01830621Phase 3Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- May 2013
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in colorectal carcinoma (CRC) comparing Napabucasin + BSC with Placebo + BSC (2 arms). Primary endpoint: Overall Survival at 36 months. Started May 2013; status: completed.
02
Drugs
napabucasin
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT01830621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01830621.